Lily Rises on Jardiance Market Share Gain as Outlook Disappoints

Updated on
  • Drugmaker gave 2016 forecasts that fell short of estimates
  • Guidance weak but growth should be `robust,' analyst says

Eli Lilly & Co. rose after saying that patients flocked to its diabetes drug Jardiance since data showed the therapy cut deaths from heart attacks and strokes.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.